WVC’s Post

Which biotech/pharma players had the biggest fundraises this past July & August? Here we're covering the 20 biggest company fundraises during the peak of summer, put together by TLDR Biotech. For a larger list of 71 biotech/pharma fundraises over this time period, comment below or send me a DM. (And if you're interested in getting market research like this, happy to chat further.) —————————— Get the top biotech and pharma industry news, straight to your inbox and all in one email - that's TLDR Biotech. 🧬🔔 #biotech #pharma #pharmanews #biotechnews #tldrbiotech 

There’s still time to participate in this year’s biotech survey. Share your thoughts and help shape the future of biopharma partnering! By completing this survey, we’ll send you a guide of 24 top tips to help you prepare for and navigate BIO International Convention, the largest annual partnering event. Find the survey here: https://lnkd.in/es-UT-6K #biopharma #biopharmapartnering #biotech

Opyl has partnered with L39 Capital Pty Ltd to launch an AI Biotech Fund. This fund will leverage our proprietary TrialKey technology, targeting $100M in AUM within 36 months. TrialKey’s predictive power will help us identify high-return biotech stocks, initially focusing on the US and Australia with over 200 annual inflection points. Book a demo:https://lnkd.in/grvHkpXN Marketing and investor enquiries: bernice.averion@opyl.ai  #aiinbiotech #clinicaltrials #opyl #investment #biotech #biopharma #medtech #pharmaceuticals #healthcare #softwaredevelopment #asx #investing"

this survey allows biotechs to show pharma companies what really matters to them when it comes to partnering

We at Wheeler Bio, Inc. are acutely aware of the unique challenges facing new and emerging biotechs and have built our company around serving these needs. From building our process platform to fit these needs using: ➡ "Right scale" bioreactors ➡ Phase-appropriate strategies ➡ Modular work packages To removing longstanding barriers for innovators by: ➡ Aligning services to our clients' fundraising milestones ➡ Ensuring processes are client-owned ➡ Clearly defining and adhering to proposed scopes We are the one-stop solution for biotechs seeking to advance their drug program from discovery to clinical trials. Check out our newest blog where we detail the main challenges to the biotech journey and how Wheeler is well-positioned to solve them! #Biotech #BIO2024 #CMC #CDMO

📢 Exciting News! AmpleLogic is proud to be a Silver Sponsor at Federation of Asian Biotech Associations (FABA)! On August 7th at 11 AM, our very own Mr. Manne Venkanna Chowdary will take the virtual stage to discuss "Harnessing Digital Technologies for Enhanced Drug Manufacturing in Pharma." We're thrilled to be part of this insightful session! #AmpleLogic #FABA #DigitalTransformation #PharmaInnovation #IndustryLeadership

Biotech initial public offerings (IPOs) are essential for funding emerging drugmakers, but recent market fluctuations have made the landscape more challenging. Stay informed with this regularly updated database that tracks IPO activity, company performance, and investment trends in the biotechnology sector from BioPharma Dive: https://lnkd.in/evy-5Kps

In an exclusive interview with Global Business Report (GBR), Subodh Deshmukh, CEO of Biologics and President of Development, along with Ramesh Subramanian, CCO of Aragen Life Sciences, share insights about the growth of biologics in the USA and key insights on why automation is important in the CDMO and CRO segments in the current scenario. Click on the link below to get complete insight into the current dynamics of the CDMO and CRO industry. #interview #cdmo #cro #drugdevelopment #biologics #usa #lifesciencesupdates #markettrends #exclusive

Thoughts on this? >> Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech

📢 Attention, time change! May 16th, at 14:40, Stage 5    ✅ "From risk to remedy – Polish biotech's answers to sustain stable drug and diagnostics supply during shortages"  🎤 Join the discussion panel at Impact CEE, where Konstantin Matentzoglu (Polpharma Biologics) alongside Katarzyna Rolle (Polish Academy of Sciences), Dariusz Adamusiński (MedTech Poland), and moderator Joanna Bekker (Polityka Insight) will discuss how collaboration between businesses and science can strengthen supply chains when needed. Don't miss this important discussion! #IMPACTCEE #Innovation #Biotechnology #PolpharmaBiologics